In April 2008, the company invested RMB 130.7million (USD 19 million) to acquire a  bio-pharmaceutical company located at Hi-Tech Development Zone in Hefei, to set up a subsidiary – Anhui Biochem (Bio-Pharma) Co., Ltd – for R&D and manufacture of the finished pharmaceutical products (FPPs) for hepatitis B and HIV/AIDS.